Latest dacarbazine Stories

MELBOURNE, Australia, Oct. 25, 2012 /PRNewswire/ -- Specialised Therapeutics Australia Pty Ltd today announced that abstracts for the upcoming Society for Melanoma Research meeting have been published online in the organization's official journal at http://onlinelibrary.wiley.com/doi/10.1111/pcmr.12023/abstract. The publication includes an abstract reviewing results from a phase III metastatic melanoma study with ABRAXANE(®) (nanoparticle albumin-bound paclitaxel). In the...

Researchers presented findings on Monday at the American Society of Clinical Oncology meeting in Chicago of two experimental treatments that treat advanced melanoma. The two experimental treatments, known as Dabrafenib and Tramentinib, are being developed by GlaxoSmithKline and are showing promising results to combat the deadly skin cancer. The researchers said that the trial on Tramentinib included 322 people, 214 of which took the experimental drug while the rest did chemotherapy....

Decision Opens New Doors to Long-Awaited Combination Trials WASHINGTON, Aug. 17, 2011 /PRNewswire-USNewswire/ -- Melanoma patients who have long faced a bleak treatment landscape are gaining a new approach for treating the deadliest form of skin cancer. The Food and Drug Administration today announced the approval of Zelboraf, known as vemurafenib or PLX4032 during testing, well ahead of the approval deadline. Zelboraf is the first drug to treat advanced melanoma by targeting a specific...

PARSIPPANY, N.J., Aug. 17, 2011 /PRNewswire/ -- With the US Food and Drug Administration (FDA) approval today of Zelboraf(TM) (vemurafenib), a first-in-class personalized treatment for patients with unresectable (inoperable) or metastatic melanoma with a BRAF V600E mutation as detected by an FDA-approved test, Daiichi Sankyo prepares to enter the US cancer market with its first oral, targeted anti-cancer therapy. "The Zelboraf approval is not only a significant milestone for these...

Second melanoma drug approved this year that improves overall survival SILVER SPRING, Md., Aug. 17, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Zelboraf (vemurafenib), a drug to treat patients with late-stage (metastatic) or unresectable (cannot be removed by surgery) melanoma, the most dangerous type of skin cancer. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO) Zelboraf is specifically indicated for the treatment of patients with...

A new study found that people with advanced melanoma who were treated with Bristol-Myers Squibb Co.'s Yervoy plus chemotherapy lived an average of two months longer than people who got chemotherapy alone. The study is the first to show that combining chemotherapy and an immune-system treatment is safe and effective for patients with advanced melanoma. It is also the second major trial to show Yervoy (ipilimumab), a new type of immunotherapy drug, can improve survival in patients with the...

PARSIPPANY, N.J. and TOKYO, May 11, 2011 /PRNewswire/ -- Daiichi Sankyo announced that applications have been submitted for market approval for vemurafenib (PLX4032/RG7204) for the treatment of metastatic melanoma to the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Additionally, a pre-marketing application for approval for a companion diagnostic test has been submitted in the U.S.; the test also will be registered in Europe. Vemurafenib is an oral,...

-FDA decision on immunotherapy means first new treatment option in more than a decade becoming available- WASHINGTON, March 25, 2011 /PRNewswire-USNewswire/ -- Thirteen years of waiting is now over for melanoma patients. That's how long it's been since the last therapy became available to treat the most lethal form of skin cancer - melanoma. The FDA today announced approval of Yervoy, an immunotherapy treatment for advanced melanoma. The drug will be used to treat melanoma patients...

Rush University Medical Center enrolls first US patientRush University Medical Center has just enrolled the first U.S. patient in an international clinical trial testing a novel drug to treat certain kinds of melanoma, a deadly skin cancer that in its advanced stages currently has few effective treatments.Rather than blocking or killing all rapidly dividing cells, whether malignant or not, the drug, called nilotnib, is one of a new class of agents that have been designed to sabotage aberrant...

Use of an experimental targeted drug to treat metastatic melanoma tumors with a specific genetic signature was successful in more than 80 percent of patients in a phase 1 clinical trial. Results of the trial of PLX4032, an inhibitor of a protein called BRAF that is overactive in more than half of all melanomas, appear in the August 26 New England Journal of Medicine."Metastatic melanoma has a devastating prognosis and is one of the top causes of cancer death in young patients," says...